Breaks Categories: News

WednesdayJul 26, 2017 9:23 am

HempNewsBreaks – ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Issues Update on Construction and Expansion Activities

ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning provided an update on its construction and expansion timelines for its Vanluven and Kimmett facilities, both of which are located in Napanee, Ontario. Per the update, ABcann’s plans to commence construction at its Kimmett facility in the third quarter of 2017 remain on schedule, and the previously announced plans for a 71,000 square foot Phase 1 project have been expanded to 100,000 square feet. Additionally, the company has initiated immediate expansion and construction efforts at its current production facility at Vanluven with the goal of doubling production capacity in order to…

Continue Reading

MondayJul 24, 2017 9:40 am

HempNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Subsidiary Files Record of ‘CBD Magic Hemp Series’ Product Line Ahead of Impending Launch

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that its wholly-owned foreign enterprise, CBD Biotechnology Co. Ltd., has officially filed a record of its first line of non-industrial hemp-infused skin care products with the China Food and Drug Administration (CFDA). These products, which comprise the new ‘CBD Magic Hemp Series’ skin care line, are expected to launch in late August and early September of this year, positioning CBD Biotechnology as a first-mover in an untapped segment of China’s skin care industry. “As one of the first skin care products containing CBD extract marketed in China, CBD Magic Hemp…

Continue Reading

ThursdayJul 20, 2017 9:05 am

HempNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Commences Lab Work with National Research Council of Canada

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced the start of laboratory work under its collaborative research project with the National Research Council of Canada (“NRC”). “We are delighted to have commenced formulation development and characterization work together with the NRC,” John Docherty, president of Lexaria Bioscience, stated in the news release. “The NRC team has extensive knowledge and experience in the field of lipid based delivery systems relating to pharmaceutical products, natural health products and functional foods. This collaboration will significantly assist Lexaria in further developing and characterizing its IP portfolio.” Moving forward, several studies will be…

Continue Reading

TuesdayJul 18, 2017 12:19 pm

HempNewsBreaks – Algae Dynamics Corp. (ADYNF) Featured in Exclusive Audio Interview by HempWire

Multifaceted financial news and publishing company HempWire (“HW”) this morning announced the online availability of an exclusive audio interview with Algae Dynamics Corp. (OTCQB: ADYNF). In the interview, Paul Ramsay, president and chairman of Algae Dynamics, provides insight into the company’s operational focus on the development of unique health products and pharmaceuticals utilizing cannabis, hemp and algae oils. “We're working with cannabis in isolation, but we are also formulating different combinations of algae mixed with cannabis oils. It's quite an interesting program and quite exciting given the health benefits,” Ramsay noted. “We're doing this because we have a lot of…

Continue Reading

TuesdayJul 18, 2017 9:00 am

HempNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Awarded Australian Patent Protecting Cannabis Infused Edibles

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that the Australian Patent Office has granted patent #2015274698, which protects Lexaria’s method of improving absorption, speed of onset and taste of cannabinoid active agents in edible products. The term of the patent is 20 years from June 10, 2015. “We are very pleased to have received this patent which effectively covers all cannabis oil extract formulated edibles utilizing our technology in Australia,” Chris Bunka, CEO of Lexaria, stated in the news release. “This patent award allows us to confidently enter the recently legalized Australian cannabis marketplace where we will…

Continue Reading

FridayJul 14, 2017 12:11 pm

HempNewsBreaks – MassRoots, Inc. (MSRT) Shares Fall on Close of Odava Acquisition

Shares of MassRoots (OTCQB: MSRT) dipped 9% after the company this morning said it has closed the previously announced acquisition of Odava, Inc. in exchange for cash and common stock consideration. Following the acquisition, the company is now able to offer dispensaries a complete suite of software to manage their regulatory compliance, restructure their supply chain, and develop consumer loyalty programs. "The Odava acquisition diversifies our revenue streams while also enabling the platform integrations necessary to effectively monetize MassRoots' audience," MassRoots chief executive officer Isaac Dietrich stated in the news release. To view the full press release, visit: http://nnw.fm/u2GMT About MassRoots…

Continue Reading

FridayJul 14, 2017 9:23 am

HempNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Reports Financial Results for Fiscal Year Ended March 31, 2017

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced its financial results for the fiscal year ended March 31, 2017. “In fiscal 2017, our major accomplishments include the advancement of our phytocannabinoid patent filing portfolio to large market indications,” Ram Mukunda, CEO of IGC, noted in the news release. “And in order to keep this focus on the medical cannabis industry, we disposed of our low-margin iron ore and electronic trading businesses, and retired about 10% of our outstanding common stock; thus reducing revenue, PP&E, and stockholder’s…

Continue Reading

WednesdayJul 12, 2017 12:06 pm

HempNewsBreaks – ABcann Global Corporation (TSXV: ABCN) (OTC: ABCCF) Lists Common Shares on OTCQB Venture Market and Frankfurt Stock Exchange

ABcann Global Corporation (TSXV: ABCN) (OTC: ABCCF) this morning announced that its common shares have been approved for trading on the OTCQB Venture Market, under the symbol ‘ABCCF’, and on the Frankfurt Stock Exchange, under the symbol ‘23Q’. The company’s common shares will also continue to trade on the TSX Venture Exchange under the symbol ‘ABCN’. The company expects that these listings will provide a number of long-term benefits, including greater visibility and convenience for investors in the United States and Europe. As a result of this expanded base of potential shareholders, ABcann will likely benefit from enhanced liquidity moving…

Continue Reading

MondayJul 10, 2017 10:09 am

HempNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Enters Definitive Agreement for $15 Million Investment

ABcann Global Corporation (TSXV: ABCN) this morning announced the signing of a definitive subscription agreement with Cannabis Wheaton Income Corp. (TSXV: CBW). Under the terms of the deal, Cannabis Wheaton has agreed to purchase $15 million of ABcann common shares at an agreed-upon valuation of $2.25 per share. Completion of this first subscription, which forms part of a larger phased investment by Cannabis Wheaton, is expected to occur by July 31, 2017, subject to customary closing conditions. “We are pleased to move forward with the initial funding phase of our partnership with Cannabis Wheaton and to welcome them as new…

Continue Reading

MondayJul 10, 2017 9:11 am

HempNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Enters Research and Development Collaboration with ATERA SAS

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its entry into a research and development collaboration with ATERA SAS of France, a leading tissue engineering company specializing in the development of advanced human tissue models. Under the terms of the agreement, ATERA will develop 3D human skin models of Epidermolysis Bullosa (EB) to be used in the evaluation of INM-750, InMed’s proprietary topical cannabinoid product candidate targeted as a therapy in EB and other potential dermatological and wound-healing applications. “INM-750 has demonstrated significant potential in pre-clinical models to address symptomatic improvement of EB including…

Continue Reading